All In Biotech

Drug Trial Radar · NCT00135304

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone

Last checked: Nov 19, 2026Latest source record: Feb 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

170

Actual

Start

Aug 2005

Primary completion

Oct 2006

Study completion Dec 2006

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P) product.

Conditions

  • Secondary Hyperparathyroidism

Interventions

  • Sensipar®Drug

    Cinacalcet hydrochloride

  • Vitamin DDrug

    Vitamin D administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achieving the NKF-K/DOQI targets for both biPTH (80-160 pg/mL, equivalent to iPTH 150-300 pg/mL) and Ca x P (less than 55 mg^2/dL^2) during the assessment phaseTime frame: Weeks 17 - 27

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.